Veracyte, Inc.
Veracyte is a pioneering genomic diagnostics company. Our tests provide trustworthy and actionable ANSWERS that improve care throughout the patient journey. We ask the right questions and provide answers that give physicians and patients a clearer path forward. Our tests leverage innovations in genomic technology and machine learning to enable more confident diagnostic, prognostic and treatment decisions in challenging diseases such as thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis. We are creating new standards of care by enabling more patients to avoid unnecessary invasive procedures, speeding time to diagnosis and treatment while removing costs from the healthcare system. We are changing today`s clinical practice standards. We are making a difference in the lives of physicians and patients. We are doing something real.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
Our Mission
To answer important questions throughout the patient journey informing better diagnosis and treatment decisions.
Our Vision
To improve outcomes for patients all over the world at every step of their journey.
What We Do
Our Approach
As a pioneer in genomic diagnostics Veracyte's novel approach consistently brings to bear solutions that have not been considered in traditional diagnostics. We begin by asking the right questions to inform significant changes to patient care, enabling actionable, accurate and appropriate answers for each and every patient, while saving millions of dollars in unnecessary surgeries and other interventions.
This is the Age of Evidence
Veracyte sits solidly at the forefront of a massive shift from experience-based medicine to redefined diagnostic clarity. Our consistent results are achieved by:
Our Technology
Veracyte is setting new standards in translating complex genomic data into clinically meaningful information that changes patient care. We develop our genomic classifiers by leveraging innovations in clinical science, RNA sequencing and machine learning to answer specific clinical questions. Today, these answers can often only be obtained using patient samples obtained through surgery.
Our machine learning approach recognizes patterns of genes that correspond with “clinical truth” (for example: a benign thyroid nodule). We use next-generation RNA sequencing to extract rich feature sets – gene expression, DNA variants, RNA fusions, mitochondrial DNA content and loss of heterozygosity – from the RNA transcriptome of patient samples obtained through minimally invasive procedures. These are the “pixels” that enable us to create the highest-resolution genomic picture possible.
We train our proprietary machine learning algorithms to interpret this vast genomic data using large numbers of diverse patient samples that represent the broad spectrum of disease that our genomic tests may likely encounter in a clinical setting. In some cases, we deploy ensemble algorithms – or, “algorithms of algorithms” – to differentiate between complex biologies.
As scientific understanding continues to progress, additional features that inform disease status, such as more-refined genomic features or even imaging data, can potentially help us identify “clinical truth” with ever-more precision, enabling development of tests that provide even clearer answers to important clinical questions.